



Company Contact

Ben Holmes
CEO
Ben.Holmes@nanochon.com
(703) 994-6099

Management Team

Ben Holmes CEO
Nathan Castro CTO
Matthew Scherer Financial Adviser
Gary Wakeford CRO
Christopher Cannova MD Chief Medical Advisor

Advisors

Jon Dickens MD
Head of Research Sports Med
Walter Reed Medical Center

Jon Godin MD
Sports Med/Knee Specialist
Steadman, Vail CO

Tom Noonan MD
Team Physician
Colorado Rockies

Kevin Kaplan MD
Sports Med/Knee Specialist
Jacksonville Orthopedic
Institute

Dave Flanigan MD
Sports Med/Knee Specialist
Ohio State University

Legal Counsel
Matthew Cunningham
General Counsel

Intellectual Property
Darwin Rinderer
WSGR - IP Counsel

Accountant
Alan Gordon, CPA

COMPANY OVERVIEW: Nanochon is finalizing development of a technology for use within the orthopedic market. Nanochon has developed a novel device to replace damaged cartilage within the knee in a market that is significantly under served. The initial target market is comprised of active adult patients between the ages of 18 – 55. The company has completed the first step in setting a new clinical standard for cartilage restoration and is raising seed capital to take the next steps.



UNMET NEEDS: Current methodology utilizes total joint replacement in solving joint defects, but the limited lifespan of replacement joints limits their use to patients aged 55 or older. This leaves patients between the ages 18 and 55 suffering from cartilage damage, traumatic injury, or early stage cartilage loss with limited treatment options. Current alternatives for this subset of patients all suffer from common short falls:

- ✓ exorbitant costs (\$10K - \$30K)
- ✓ Long procedural wait times (up to 8 months due to the need to cultivate cells)
- ✓ Poor long-term results



SOLUTION: NANOCHON™

- ✓ Replaces lost or damaged cartilage & encourages new growth
- ✓ Is 3-D printed, is made of novel proprietary nano and micro material
- ✓ Is an orthopedic load bearing implant
- ✓ Has the potential to deliver faster and more successful recoveries for patients, while reducing costs to health providers, payers, and patients
- ✓ Goal is to become the new clinical standard for complex joint repair

COMPANY MILESTONES: The Company has already made very significant headway in demonstrating the efficacy and feasibility of the technology working on a very slim budget.

- ✓ Accepted into the Johnson & Johnson Innovation JLABS program
- ✓ Completed FDA pre-submission. Center for Disease and Radiological Health (CDRH) concurs with our proposed pre-clinical and clinical roadmaps.
- ✓ Initial large animal study completed with strong evidence of product efficacy.
- ✓ Hospitals and primary investigators standing by to conduct 15 patient human study (Brisbane Australia)

MARKET OPPORTUNITY: Initially there are 300K – 400K patients we feel would directly benefit from our technology in the near term representing somewhere between a \$550M and an \$825M market. As the technology gains market acceptance and proves out its' utility, the initial target market has the potential to expand to 700K procedures per year far exceeding the \$1B mark. In launching the technology, we will focus on sports medicine surgeons who own their own surgicenters as a market segment. These surgeons see the highest volume of these patients and make purchasing decisions in the practice. Nanochon has developed a clear path to securing reimbursement for this technology, which will pave the way for large scale adoptions in acute care hospitals as well.

FINANCING: The company has thus far raised close to \$500K from grants and a small pool of initial investors from the following sources:

- ✓ Awarded NSF Phase I grant dollars
- ✓ NSF – I-CORPS, Wilson Sonsini Investment Fund, Pediatric Ortho Society of NA
- ✓ Friends and Family Investments

The Company has determined that an additional \$1 Million will be required to fully validate the technology, prepare for GMP manufacturing and most importantly position Nanochon to conduct a first in man clinical trial.

DEAL TERMS: Nanochon is raising the \$2 Million seed round:

- \$4.5 million pre-money valuation, preferred shares
- Terms set by VC, term sheet in 2021
- Committed syndicate including notable angel groups and a strategic